Portfolio

Aria CV, Inc.

Aria is developing the first implantable medical device for treating Pulmonary Hypertension (PH), a deadly disease that strikes in the prime of life. In patients with PH, high blood pressure in the lungs increases the workload on the heart and greatly limits physical activity, resulting eventually in right heart failure and death. Aria’s device reduces workload on the heart and is expected to improve both quality and duration of life.


Arrinex, Inc.

Arrinex has developed a disruptive cryotherapy technology for treating chronic nasal allergy symptoms: congestion and drainage.  The Arrinex technology replicates surgical results with a non-invasive 15-minute procedure that is performed in the ENT office under local or topical anesthesia. In patients treated with the Arrinex technology, the procedure has been safe and the long term results satisfying to patients and physicians. 


Autonomix, Inc.

Autonomix is developing technologies and catheter devices to locate and record neural signaling patterns coupled to individual organs.  The Company’s initial applications are for high resolution low noise cardiac electrophysiology mapping, and detecting and quantifying neural activity in the renal arteries - a potentially important aspect of renal denervation therapy (RDN). 


Breathe Technologies, Inc.  

Breathe Technologies is developing novel COPD therapy devices that are designed to significantly improve existing ventilation and supplemental oxygen therapy products, and provide dramatic quality of life benefits for COPD patients that require assisted ventilation or oxygen therapy.   


C2 Therapeutics, Inc. 

C2 Therapeutics has developed novel disposable devices to treat Barrett’s Esophagus, an early precursor to esophageal cancer.  C2 Therapeutics’ CryoBallon Ablation System consists of a disposable hand-held controller, a conformable clear balloon and is delivered through a bronchoscope.   The CryoBallon Ablation System is superior to existing RF balloon ablations as it does not require a sizing procedure, any capital equipment, and benefits from an easier and quicker procedure. In January 2017 C2 Therapeutics was acquired by Hoya Pentax.


Cagent Vascular, LLC

Cagent is developing novel interventional devices for the treatment of peripheral artery disease featuring their serrated angioplasty balloon technology, which allows for controlled lower pressure dilatation of vessels with calcifications. This approach could also improve vessel wall uptake of therapeutics in post dilatation treatment with drug coated balloons.  


Chestnut Medical, Inc.

Chestnut Medical is developing novel devices for interventional neuroradiology procedures.  The Company’s flagship product, the Pipeline aneurysm device, is a fine mesh tubular device that is used to isolate an aneurysm from blood flow without the need for coils.   In June 2009 Chestnut Medical was acquired by ev3.


CV Ingenuity, Inc.

CV Ingenuity is developing drug eluting balloon and coating technology for use in peripheral and cardiac vascular interventional procedures to reduce the rate of restenosis.  CV Ingenuity was acquired by Covidien in December 2012.


Lumo Body Tech Inc.

Lumo Body Tech is a startup developing a novel wearable sensor/smartphone system to address poor posture and posture related back pain.  Their Lumoback and Lumo Lift devices are wearable sensor enabled devices that are placed on the body to track position and motion and integrate with smartphone and cloud based algorithms.


Marblehead Medical LLC

Marblehead Medical is developing a device to optimize the efficacy of mechanical thrombectomy in interventional neurovascular procedures. Marblehead’s BOSS device will feature improved support for distal access devices, improved suction efficiency, diminished risk of emboli, and increased luminal diameter to accommodate modern distal access catheters. 


Medina Medical Inc.

Medina Medical has developed an revolutionary neurovascular mesh coil implant to address the unmet need of treating intricate bifurcation and wide necked giant aneurysms, which represent 60% of all brain aneurysm cases today.  The Medina device represents a true next generation, single-device solution for aneurysms, which can be deployed rapidly with no need for balloon protection or other device to protect from downstream coil loss. The Company was acquired by Medtronic in 2015.


MoMelan Technologies, Inc. 

MoMelan Technologies has developed the ‘Epidermal Expansion System (EES),’ a point-of-care, compact medical device that will provide physicians with the first viable approach to perform standardized epidermal expansion and skin grafting in less than one hour. MoMelan’s technology provides the ability to significantly expand (up to 100x) the size of an autologous epidermal skin graft with high reliability and repeatability.  Momelan was acquired by KCI in 2013.


NeoCis Inc.

NeoCis has developed the YOMI small profile robotic guidance system for the dental implant market, enabling implant specialists to place implants easily and precisely, which improves financial results and patient outcomes. The NeoCis system has numerous advantages over conventional surgery, which covers the majority of currently placed implants, and over drill guides, which are currently the best way to guarantee accuracy for complicated cases but which are less accurate and take days to prepare.  NeoCis received FDA approval for their YOMI robot in 2017.


Neptune Medical, Inc.

Neptune Medical is developing novel gastroenterology technologies and products to assist in diagnosis and treatment of diseases of the small intestine.   The Company has developed three separate product concepts to assist in  navigation, guidance and imaging.


NeuroSave, Inc.

NeuroSave is developing a therapeutic hypothermia system to locally cool the brain via esophageal lavage with cold saline.   Their device can cool rapidly and deeply, providing potential clinical benefits for stroke, cardiac arrest and cardiac surgery patients. 


Palmera Medical, Inc.

Palmera Medical is developing a suite of tools for endovascular treatment of ischemic stroke, particularly large vessel occlusion of the intracranial vessels. Endovascular techniques for the treatment of stroke have been evolving for more than 20 years, and recent demonstration of the benefit of these therapies has led to a rapid growth in stroke treatments.  Palmera plans to develop several devices that can be used in conjunction to reestablish flow in large vessel occlusion (LVO) of intracranial vessels in the setting of acute ischemic stroke.  


Paradromics Inc.

Paradromics is developing a high bandwidth neural interface that will serve as the basis for next generation neural prosthetics.  Their Neural Input Output Bus (NIOB) will act as a broadband modem for the brain, allowing it to communicate with computers and biomedical devices. This connectivity will improve the quality of life for those suffering from neurodegenerative diseases and severe sensory or movement disorders.


Pulson Inc.

Pulson has developed the CounterPace wearable sensor-based smart feedback system to make aerobic exercise easier, more effective, safer and more fun. Pulson's initial product is designed to immediately and dramatically enhance athletic performance via real-time continuous guidance that enables increases in speed and endurance.  Pulson is also leveraging its technology platform to improve quality of life and health benefits for patients with very limited exercise capacity through modifications to commonly utilized programmable cardiac technologies.


ReLign Corporation

ReLign has developed a novel integrated system for arthroscopic interventions.  Their system includes integrated irrigation and aspiration, RF and plasma ablation, cutting and coagulation, and mechanical debriders and burrs to allow the user to perform complete procedures without tool changes.


Respirix, Inc. 

Respirix is developing a novel approach to monitor CHF patients at home. Timely detection and intervention for CHF patients with worsening condition has been shown to dramatically reduce hospitalization and mortality. Respirix’ approach involves using precise analysis of breathe exhalation to monitor cardiogenic oscillations, which may be a more sensitive indication of pulmonary artery compliance.  


RetroVascular, Inc.

RetroVascular is developing a family of tools to allow the interventional cardiologist to treat chronic total occlusions, or CTOs, easily and rapidly, using a retrograde approach.  Current research involves the use of novel plasma pulse technology in catheters to create channels through CTOs quickly and safely.


RODO Medical Inc.

RODO Medical has developed a unique dental implant retention system based on shape memory metal technology. Current screw or cement retention methods used in implant prosthetic dentistry are technically difficult, time consuming, and have long term complications or difficulties in revision.  The RODO Smileloc system retains the implant prosthesis utilizing medical grade nitinol. The crown can be removed by activating this nitinol component. The delivery or removal process takes minutes without damaging the crown or abutment.


Sevident, Inc.

Sevident is developing assays built on their patented molecular net technology that can allow extremely low limits of detection and fast test results.  The technology does not require the presence of whole, metabolically active bacteria in a given sample, because it also contains capture molecules to detect protein signatures and the bits and pieces of bacteria, thereby increasing sensitivity. Sevident's molecular net platform is highly flexible, with rapid product development cycles -- a new assay can move from design to working prototype in less than a month, due to the technology's simple design and straightforward manufacturing processes.


ThrombX Medical, Inc.

ThrombX Medical is a startup developing a next generation stent retriever device for ischemic stroke. The premise is that rapid TICI 3 perfusion needs to be achieved for better outcomes, and current stent retrievers cannot perform better due to issues with clot capture.    



545 Middlefield Road       Suite 205     Menlo Park   California  94025                           tel /fax 650 322 3475